A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Similar documents
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

egfr > 50 (n = 13,916)

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

CVD risk assessment using risk scores in primary and secondary prevention

Atherosclerotic Disease Risk Score

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Morbidity & Mortality from Chronic Kidney Disease

Protecting the heart and kidney: implications from the SHARP trial

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Lipid Panel Management Refresher Course for the Family Physician

Review of guidelines for management of dyslipidemia in diabetic patients

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Magnesium intake and serum C-reactive protein levels in children

Antihypertensive Trial Design ALLHAT

The Framingham Coronary Heart Disease Risk Score

CLINICAL OUTCOME Vs SURROGATE MARKER

Patients with the metabolic syndrome are at increased risk

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.

When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes

CARDIO-RENAL SYNDROME

Supplementary Online Content

ATP IV: Predicting Guideline Updates

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

New Guidelines in Dyslipidemia Management

Managing Chronic Kidney Disease: Reducing Risk for CKD Progression

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

Chronic Kidney Disease as cardiovascular risk predictor Evidence based clinical management. Fabio Mazza

Inflammation in Renal Disease

Supplementary Online Content

CVD Prevention, Who to Consider

Correlation of novel cardiac marker

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

The Diabetes Link to Heart Disease

Lipid Management 2013 Statin Benefit Groups

hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER

ACCP Cardiology PRN Journal Club

Journal of the American College of Cardiology Vol. 54, No. 25, by the American College of Cardiology Foundation ISSN /09/$36.

journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract

Of the 1.5 million heart attacks

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010

New Guidelines in Dyslipidemia Management

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Fasting or non fasting?

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Supplementary Appendix

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

The TNT Trial Is It Time to Shift Our Goals in Clinical

C-REACTIVE PROTEIN AND LDL CHOLESTEROL FOR PREDICTING CARDIOVASCULAR EVENTS

surtout qui n est PAS à risque?

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Supplementary Online Content

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Supplementary Online Content

CARDIOVASCULAR RISK ASSESSMENT ADDITION OF CHRONIC KIDNEY DISEASE AND RACE TO THE FRAMINGHAM EQUATION PAUL E. DRAWZ, MD, MHS

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study

Cardiovascular Complications of Diabetes

American Academy of Insurance Medicine

Supplementary Online Content

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.

Cardiovascular Risk Among Adults With Chronic Kidney Disease, With or Without Prior Myocardial Infarction

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Beta-blockers for coronary heart disease in chronic kidney disease

TREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009

The Clinical Unmet need in the patient with Diabetes and ACS

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

Supplemental Table 1. Standardized Serum Creatinine Measurements. Supplemental Table 3. Sensitivity Analyses with Additional Mortality Outcomes.

PCSK9 Inhibitors and Modulators

Changing lipid-lowering guidelines: whom to treat and how low to go

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes

AGING KIDNEY IN HIV DISEASE

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Cedars Sinai Diabetes. Michael A. Weber

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Traitements associés chez l hypertendu: Statines, Aspirine

Estimated glomerular filtration rate as a predictor of secondary outcomes in Japanese patients with coronary artery disease

DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose

Contemporary management of Dyslipidemia

Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study

JMSCR Vol 07 Issue 01 Page January 2019

Transcription:

A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were followed over a mean of 8 years for the occurrence of first CV events. These included nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization procedures, and CV death. 1 Kaplan-Meier survival curves are shown according to 4 groups, based on whether participants were above or below the median C-reactive protein (CRP) value (1.52 mg/l) and the median low-density lipoprotein cholesterol (LDL-C) value (123.7 mg/dl or 3.20 mmol/l). The results show that CRP and LDL-C are not strongly correlated, suggesting that they detect different high-risk groups. Evaluation of both CRP and LDL-C may be more predictive than either marker alone. CRP may be a stronger predictor than LDL-C: the high-crp/low-ldl-c group had a lower probability of event-free survival than the low-crp/high- LDL-C group. 1 Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565. 1

1 in 4 adults have diabetes or the metabolic syndrome A 2001 survey of 195,000 US adults aged 18 revealed an overall 7.9% prevalence of diabetes, giving an estimated 18 million adults with diabetes in 2002. 1 The highest prevalence of diabetes is seen in blacks (11.2%), followed by Hispanics (9.0%), other (8.2%), and whites (7.2%). In addition, the American Diabetes Association estimates that there may be as many as 8 million currently undiagnosed diabetics in the United States. 2 The metabolic syndrome, a predisposing factor to development of diabetes and CV disease, has an overall prevalence in the US adult population of 23.7%. An estimated 47.7 million adults in this country are now affected. 3 Hispanics show the highest rates of the metabolic syndrome, a 31.9% prevalence. Overall, diabetes or the metabolic syndrome is present in one out of four adults in the United States. 1 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79. 2 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20. 3 Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359. 2

Higher prevalence of CV risk factors in adults with vs without diabetes Estimates for CV disease risk factors were calculated from data on 9496 adults with diabetes and 105,493 adults without diabetes. 1 Modifiable risk factors were more prevalent in adults with diabetes than without diabetes (P < 0.001): Hypertension, 56% vs 22% High cholesterol, 41% vs 20% Obesity, 78% vs 57% Low physical activity, 66% vs 56% 1 Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: Prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002;162:427-433. 3

Level of kidney function: An independent risk factor for CV disease Manjunath et al studied the relation between level of kidney function and risk of CV disease in a community cohort. 1 Study subjects were enrolled in the Atherosclerotic Risk in Communities (ARIC) study, an ongoing, community-based longitudinal study of coronary heart disease and stroke. The present study included 15,350 subjects recruited from communities in Mississippi, North Carolina, Minnesota, and Maryland. Kidney function was assessed by glomerular filtration rate (GFR), which was estimated from serum creatinine values. Study subjects were stratified as follows: Normal kidney function: GFR 90 to 150 ml/min/1.73m2 Mild decrease in kidney function: GFR 60 to 89 ml/min/1.73m2 Moderate to severe decrease in kidney function: GFR 15 to 59 ml/min/1.73m2 As shown, Kaplan-Meier survival analysis showed a greater probability for CV disease in subjects with lower GFR during a mean follow-up of 6.2 years. The adjusted hazard ratio was 1.38 (95% CI, 1.02 to 1.87; P = 0.038) for the group with moderate to severe decrease in GFR versus the group with normal GFR. The findings from the ARIC study extend previous studies demonstrating an association between kidney function and CV risk in patients with CV disease or at high risk for CV disease. The ARIC results demonstrate that level of kidney function is an independent risk factor for CV disease in the community. 1 Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55. 4

Increased prevalence of dyslipidemia in patients with vs without chronic kidney disease The prevalence of dyslipidemia is increased in patients with chronic kidney disease (CKD) relative to the general population. However, the specific type and severity can vary depending on severity of chronic kidney disease.1 In chronic kidney disease without proteinuria, the lipid profile is similar to that observed in the metabolic syndrome, with elevated triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C), and minimally elevated LDL-C. However, patients with chronic kidney disease also have higher amounts of small, dense LDL-C (not shown) and lipoprotein (a) [Lp(a)] than the general population. In chronic kidney disease with proteinuria, LDL-C, triglycerides, and Lp(a) are elevated and HDL-C is decreased. Thus, patients with chronic kidney disease should be screened for dyslipidemia. 1 Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S152-S156. 5